DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Optimized spatial configuration of heterogeneous biocatalysts maximizes cell-free biosynthesis of ω-hydroxy and ω-amino acids
Cell-free biocatalysis is gaining momentum in producing value-added chemicals, particularly in stepwise reaction cascades. However, the stability of enzyme cascades in industrial settings is often compromised when free enzymes are involved. In this study, we have developed a stable multifunctional heterogeneous biocatalyst coimmobilizing five enzymes on microparticles to transform 1,ω-diols into 1,ω-hydroxy acids. We improved the operational efficiency and stability of the heterogeneous biocatalyst by fine-tuning the enzyme loading and spatial organization. Stability issues are overcome through postimmobilization polymer coating. The general applicability of this heterogeneous biocatalyst is demonstrated by its scale-up in both batch and packed bed reactors, allowing a product yield of >80%. The continuous process is fed with H2O2 as the oxygen source, reaching a space-time yield (STY) of 0.76 g·L–1·h–1, maintained for the first 12 h. Finally, this flow system is telescoped with a second plug-flow reactor packed with a different heterogeneous biocatalyst integrating an additional transaminase. As a result, this 6-enzyme 2-reactor system sequentially transforms 1,ω-diols into 1,ω-amino acids while in situ recycling NAD+, depleting H2O2, and generating O2., ERC-Co (METACELL-818089) and RETOS (SOMECS-RTI2018-094398-B-I00) projects are thanked for funding. F.L.-G. thanks IKERBASQUE for sponsoring him. S.V.-L. acknowledges the funding from ARAID. J.S.-A. thanks the FPI fellowship program of the Spanish Research Agency (PRE2019-090835) This work was performed under the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency─grant no. MDM-2017-0720 (CIC biomaGUNE). F.P. and A.I.B.-M. acknowledge the support from the SNSF (grant: 200021_192274) and the University of Bern (SELF19-03 BIORPHANDRUG)., Peer reviewed